• 1
    Khanna D, Lovell DJ, Giannini E, Clements PJ, Merkel PA, Seibold JR, et al. Development of a provisional core set of response measures for clinical trials of systemic sclerosis. Ann Rheum Dis 2008; 67: 7039.
  • 2
    Khanna D, Distler O, Avouac J, Behrens F, Clements PJ, Denton C, et al. Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS). J Rheumatol 2009; 36: 235661.
  • 3
    Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 13745.
  • 4
    Steen VD, Medsger TA Jr. The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997; 40: 198491.
  • 5
    Khanna D, Hays RD, Maranian P, Seibold JR, Impens A, Mayes MD, et al. Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Arthritis Rheum 2009; 61: 125763.
  • 6
    Merkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum 2002; 46: 241020.
  • 7
    Kallen MA, Mayes MD, Kriseman YL, de Achaval SB, Cox VL, Suarez-Almazor ME. The symptom burden index: development and initial findings from use with patients with systemic sclerosis. J Rheumatol 2010; 37: 16928.
  • 8
    McKenna SP, Doughty N, Meads DM, Doward LC, Pepke-Zaba J. The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension. Quality Life Res 2006; 15: 10315.
  • 9
    Johnson SR, Hawker GA, Davis AM. The Health Assessment Questionnaire disability index and Scleroderma Health Assessment Questionnaire in Scleroderma Trials: an evaluation of their measurement properties. Arthritis Rheum 2005; 53: 25662.
  • 10
    Poole JL, Steen VD. The use of the Health Assessment Questionnaire (HAQ) to determine physical disability in systemic sclerosis. Arthritis Care Res 1991; 4: 2731.
  • 11
    Clements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, Brennan P, et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 1993; 20: 18926.
  • 12
    Moser DK, Clements PJ, Brecht ML, Weiner SR. Predictors of psychosocial adjustment in systemic sclerosis: the influence of formal education level, functional ability, hardiness, uncertainty, and social support. Arthritis Rheum 1993; 36: 1398405.
  • 13
    Poole JL, Williams CA, Bloch DA, Hollak B, Spitz P. Concurrent validity of the Health Assessment Questionnaire disability index in scleroderma. Arthritis Care Res 1995; 8: 18993.
  • 14
    Malcarne VL, Greenbergs HL. Psychological adjustment to systemic sclerosis. Arthritis Care Res 1996; 9: 519.
  • 15
    Roca RP, Wigley FM, White B. Depressive symptoms associated with scleroderma. Arthritis Rheum 1996; 39: 103540.
  • 16
    Clements PJ, Wong WK, Hurwitz EL, Furst DE, Mayes M, White B, et al. Correlates of the disability index of the Health Assessment Questionnaire: a measure of functional impairment in systemic sclerosis. Arthritis Rheum 1999; 42: 237280.
  • 17
    Smyth AE, MacGregor AJ, Mukerjee D, Brough GM, Black CM, Denton CP. A cross-sectional comparison of three self-reported functional indices in scleroderma. Rheumatology (Oxford) 2003; 42: 7328.
  • 18
    Sultan N, Pope JE, Clements PJ, Scleroderma Trials Study Group. The health assessment questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: results from an analysis of two randomized controlled trials in early diffuse scleroderma. Rheumatology (Oxford) 2004; 43: 4728.
  • 19
    Khanna D, Furst DE, Clements PJ, Park GS, Hays RD, Yoon J, et al. Responsiveness of the SF-36 and the Health Assessment Questionnaire disability index in a systemic sclerosis clinical trial. J Rheumatol 2005; 32: 83240.
  • 20
    Rannou F, Poiraudeau S, Berezne A, Baubet T, Le-Guern V, Cabane J, et al. Assessing disability and quality of life in systemic sclerosis: construct validities of the Cochin Hand Function Scale, Health Assessment Questionnaire (HAQ), Systemic Sclerosis HAQ, and Medical Outcomes Study 36-Item Short Form Health Survey. Arthritis Rheum 2007; 57: 94102.
  • 21
    Ouimet JM, Pope JE, Gutmanis I, Koval J. Work disability in scleroderma is greater than in rheumatoid arthritis and is predicted by high HAQ scores. Open Rheumatol J 2008; 2: 4452.
  • 22
    Sekhon S, Pope J, Canadian Scleroderma Research Group (CSRG), Baron M. The minimally important difference (MID) for patient centered outcomes including Health Assessment Questionnaire (HAQ), fatigue, pain, sleep, global VAS and SF-36 in scleroderma (SSc). J Rheumatol 2010; 37: 5918.
  • 23
    Khanna D, Furst DE, Hays RD, Park GS, Wong WK, Seibold JR, et al. Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study. Ann Rheum Dis 2006; 65: 13259.
  • 24
    Schnitzer M, Hudson M, Baron M, Steele R. Disability in systemic sclerosis: a longitudinal observational study. J Rheumatol 2011; 38: 68592.
  • 25
    Cole JC, Khanna D, Clements PJ, Seibold JR, Tashkin DP, Paulus HE, et al. Single-factor scoring validation for the Health Assessment Questionnaire-disability index (HAQ-DI) in patients with systemic sclerosis and comparison with early rheumatoid arthritis patients. Qual Life Res 2006; 15: 138394.
  • 26
    Johnson SR, Glaman DD, Schentag CT, Lee P. Quality of life and functional status in systemic sclerosis compared to other rheumatic diseases. J Rheumatol 2006; 33: 111722.
  • 27
    Georges C, Chassany O, Toledano C, Mouthon L, Tiev K, Meyer O, et al. Impact of pain in health related quality of life of patients with systemic sclerosis. Rheumatology (Oxford) 2006; 45: 1298302.
  • 28
    Korn JH, Mayes M, Cerinic M, Rainisio M, Pope J, et al, for the RAPIDS-1 Study Group. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004; 50: 398593.
  • 29
    Zelenietz C, Pope J. Differences in disability as measured by the Health Assessment Questionnaire (HAQ) between patients with and without digital ulcers in systemic sclerosis: a post hoc analysis of pooled data from two randomized controlled trials in digital ulcers using bosentan. Ann Rheum Dis 2010; 69: 20556.
  • 30
    Brower LM, Poole JL. Reliability and validity of the Duruoz Hand Index in persons with systemic sclerosis (scleroderma). Arthritis Rheum 2004; 51: 8059.
  • 31
    Lawrence E, Pope J, Al Zahraly Z, Lalani S, Baron M. The relationship between changes in self-reported disability (measured by the Health Assessment Questionnaire-HAQ) in scleroderma and improvement of disease status in clinical practice. Clin Exp Rheumatol 2009; 27 Suppl 54: 327.
  • 32
    Khimdas S, Harding S, Bonner A, Canadian Scleroderma Research Group, Zummer B, Baron M, Pope J. Associations with digital ulcers (DU) in a large cohort of systemic sclerosis (SSc). Arthritis Care Res 2010: 63: 1429.
  • 33
    Stevens A, Pope JE. Retest reliabilities and variability among scleroderma patients for 4 tests of disability: support for a better measure. Presented at the Canadian Rheumatology Association Meeting, 1995. J Rheumatol 1995; 22: 1603.
  • 34
    Gazi H, Pope JE, Clements P, Medsger TA, Martin RW, Merkel PA, et al. Outcome measurements in scleroderma: results from a Delphi exercise. J Rheumatol 2007; 34: 5019.
  • 35
    Georges C, Chassany O, Mouthon L, Tiev K, Toledano C, Meyer O, et al. Validation of French version of the Scleroderma Health Assessment Questionnaire (SSc HAQ). Clin Rheumatol 2005; 24: 310.
  • 36
    Johnson SR, Baron M, Hudson M, Taillefer S, Hirsch A, and the Canadian Scleroderma Research Group. Lung VAS has incremental concurrent validity over the HAQ-DI was an outcome measure evaluating scleroderma lung disease. American College of Rheumatology Annual Meeting, San Diego, 2005. Arthritis Rheum 2005; 52 Suppl: S584.
  • 37
    Kuwana M, Sato S, Kikuchi K, Kawaguchi Y, Fujisaku A, Misaki Y, et al. Evaluation of functional disability using the health assessment questionnaire in Japanese patients with systemic sclerosis. J Rheumatol 2003; 30: 12538.
  • 38
    Morita Y, Muro Y, Sugiura K, Tomita Y, Tamakoshi K. Results of the Health Assessment Questionnaire for Japanese patients with systemic sclerosis: measuring functional impairment in systemic sclerosis versus other connective tissue diseases. Clin Exp Rheumatol 2007; 25: 36772.
  • 39
    La Montagna G, Cuomo G, Chiarolanza I, Ruocco L, Valentini G. HAQ-DI Italian version in systemic sclerosis. Reumatismo 2006; 58: 1125.
  • 40
    Khanna D, Clements PJ, Postlethwaite AE, Furst DE. Does incorporation of aids and devices make a difference in the score of the health assessment questionnaire-disability index? Analysis from a scleroderma clinical trial. J Rheumatol 2008; 35: 4668.
  • 41
    Serednicka K, Smyth AE, Black CM, Denton CP. Using a self-reported functional score to assess disease progression in systemic sclerosis. Rheumatology (Oxford) 2007; 46: 110710.
  • 42
    Guillevin L, Ortonne JP. Treatment of scleroderma. Ann Med Interne (Paris) 1983; 134: 75465. In French.
  • 43
    Ostojic P, Damjanov N. The Scleroderma Assessment Questionnaire (SAQ): a new self-assessment questionnaire for evaluation of disease status in patients with systemic sclerosis. Z Rheumatol 2006; 65: 16875.
  • 44
    Ostojic P, Damjanov N. Indices of the Scleroderma Assessment Questionnaire (SAQ) can be used to demonstrate change in patients with systemic sclerosis over time. Joint Bone Spine 2008; 75: 28690.
  • 45
    Sigl T, Ewert T, Stucki G. Patient-centered assessment of functional health in systemic sclerosis: where are we now? Z Rheumatol 2004; 63: 4639.
  • 46
    Silman A, Akesson A, Newman J, Henriksson H, Sandquist G, Nihill M, et al. Assessment of functional ability in patients with scleroderma: a proposed new disability assessment instrument. J Rheumatol 1998; 25: 7983.
  • 47
    Ruof J, Bruhlmann P, Michel BA, Stucki G. Development and validation of a self-administered systemic sclerosis questionnaire (SySQ). Rheumatology (Oxford) 1999; 38: 53542.
  • 48
    Danieli E, Airo P, Bettoni L, Cinquini M, Antonioli CM, Cavazzana I, et al. Health-related quality of life measured by the Short Form 36 (SF-36) in systemic sclerosis: correlations with indexes of disease activity and severity, disability, and depressive symptoms. Clin Rheumatol 2005; 24: 4854.
  • 49
    Pope J, Baron M, Bellamy N, Campbell J, Carette S, Chalmers I, et al. The variability of skin scores and clinical measurements in scleroderma. J Rheumatol 1995; 22: 12716.
  • 50
    Fan X, Pope J, Canadian Scleroderma Research Group (CSRG), Baron M. What Is the relationship between disease activity, severity and damage in a large Canadian systemic cohort? Results from the Canadian Scleroderma Research Group (CSRG). Rheumatol Int 2010; 30: 1205.
  • 51
    Hudson M, Impens A, Baron M, Seibold JR, Thombs BD, Walker JG, et al. Discordance between patient and physician assessments of disease severity in systemic sclerosis. J Rheumatol 2010; 37: 230712.
  • 52
    Clements PJ, Hurwitz EL, Wong WK, Seibold JR, Mayes M, White B, et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. Arthritis Rheum 2000; 43: 244554.
  • 53
    Schieir O, Thombs BD, Hudson M, Boivin JF, Steele R, Bernatsky S, et al. Prevalence, severity, and clinical correlates of pain in patients with systemic sclerosis. Arthritis Care Res (Hoboken) 2010; 62: 40917.
  • 54
    Malcarne VL, Hansdottir I, McKinney A, Upchurch R, Greenbergs HL, Henstorf GH, et al. Medical signs and symptoms associated with disability, pain, and psychosocial adjustment in systemic sclerosis. J Rheumatol 2007; 34: 35967.
  • 55
    Benrud-Larson LM, Heinberg LJ, Boling C, Reed J, White B, Wigley FM, et al. Body image dissatisfaction among women with scleroderma: extent and relationship to psychosocial function. Health Psychol 2003; 22: 1309.
  • 56
    Thompson AE, Shea B, Welch V, Fenlon D, Pope JE. Calcium channel blockers for Raynaud's phenomenon in progressive systemic sclerosis. Arthritis Rheum 2001; 44: 18417.
  • 57
    Hudson M, Bernatsky S, Taillefer S, Fortin PR, Wither J. Patients with systemic autoimmune diseases could not distinguish comorbidities from their index disease. J Clin Epidemiology 2008; 61: 65462.
  • 58
    Sandusky SB, McGuire L, Smith MT, Wigley FM, Haythornthwaite JA. Fatigue: an overlooked determinant of physical function in scleroderma. Rheumatology (Oxford) 2009; 48: 1659.
  • 59
    Hewlett S, Dures E, Almeida C. Measures of fatigue. Arthritis Care Res (Hoboken) 2011; 63: S26386.
  • 60
    Suarez-Almazor ME, Kallen MA, Roundtree AK, Mayes M. Disease and symptom burden in systemic sclerosis: a patient perspective. J Rheumatol 2007; 34: 171826.
  • 61
    Khanna D, Hays RD, Park GS, Braun-Moscovici Y, Mayes MD, McNearney TA, et al. Development of a preliminary scleroderma gastrointestinal tract 1.0 quality of life instrument. Arthritis Rheum 2007; 57: 12806.
  • 62
    Frech T, Hays RD, Maranian P, Clements PJ, Furst DE, Khanna D. Prevalence and correlates of sleep disturbance in systemic sclerosis: results from the UCLA scleroderma quality of life study. Rheumatology (Oxford) 2011; 50: 12807.
  • 63
    Bodukam V, Hays RD, Maranian P, Furst DE, Seibold JR, Impens A, et al. Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosis. Rheumatology (Oxford) 2011; 50: 3304.
  • 64
    Eypasch E, Williams JI, Wood-Dauphinee S, Ure BM, Schmulling C, Neugebauer E, et al. Gastrointestinal Quality of Life Index: development, validation and application of a new instrument. Br J Surg 1995; 82: 21622.
  • 65
    Thoua NM, Bunce C, Brough G, Forbes A, Emmanuel AV, Denton CP. Assessment of gastrointestinal symptoms in patients with systemic sclerosis in a UK tertiary referral centre. Rheumatology (Oxford) 2010; 49: 17705.
  • 66
    Muro Y, Sugiura K, Nitta Y, Mitsuma T, Hoshino K, Usuda T, et al. Scoring of reflux symptoms associated with scleroderma and the usefulness of rabeprazole. Clin Exp Rheumatol 2009; 27 Suppl 54: 1521.
  • 67
    Janiak P, Thumshirn M, Menne D, Fox M, Halim S, Fried M, et al. Clinical trial: the effects of adding ranitidine at night to twice daily omeprazole therapy on nocturnal acid breakthrough and acid reflux in patients with systemic sclerosis: -a randomized controlled, cross-over trial. Aliment Pharmacol Ther 2007; 26: 125965.
  • 68
    Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea: contents, interobserver agreement and physiologic correlates of two new clinical indexes. Chest 1984; 85; 7518.
  • 69
    Mahler D, Wells C. Evaluation of clinical methods for rating dyspnea. Chest 1988; 93: 5806.
  • 70
    Elliott MW, Adams L, Cockcroft A, Macrae KD, Murphy K, Guz A. The language of breathlessness. Am Rev Respir Dis 1991; 144: 82632.
  • 71
    Stoller JK, Ferranti R, Feinstein AR. Further specification and evaluation of a new clinical index for dyspnea. Am Rev Respir Dis 1986; 134: 112934.
  • 72
    Chhabra SK, Gupta AK, Khuma MZ. Evaluation of three scales of dyspnea in chronic obstructive pulmonary disease. Ann Thorac Med 2009; 4: 12832.
  • 73
    Yoza Y, Ariyoshi K, Honda S, Taniguchi H, Senjyu H. Development of an activity of daily living scale for patients with COPD: the Activity of Daily Living Dyspnea scale. Nihon Kokyuki Gakkai Zasshi 2009; 47: 85864.
  • 74
    Baron M, Sutton E, Hudson M, Thombs B, Markland J, Pope J, et al. The relationship of dyspnoea to function and quality of life in systemic sclerosis. Ann Rheum Dis 2008; 67: 64450.
  • 75
    Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 265566.
  • 76
    Borg G. Psychophysical basis of perceived exertion. Med Sci Sports Exerc 1982; 14: 37781.
  • 77
    Khanna D, Clements PJ, Furst DE, Chon Y, Elashoff R, Roth MD, et al. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum 2005; 52: 592600.
  • 78
    Khanna D, Yan X, Tashkin DP, Furst DE, Elashoff R, Roth MD, et al. Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. Arthritis Rheum 2007; 56: 167684.
  • 79
    Khanna D, Tseng CH, Furst DE, Clements PJ, Elashoff R, Roth M, et al, for Scleroderma Lung Study Investigators. Minimally important differences in the Mahler's Transition Dyspnoea Index in a large randomized controlled trial: results from the Scleroderma Lung Study. Rheumatology (Oxford) 2009; 48: 153740.
  • 80
    Goldin J, Elashoff R, Kim HJ, Yan X, Lynch D, Strollo D, et al. Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study. Chest 2009; 136: 133340.
  • 81
    Incalzi RA, Bellia V, Catalano F, Scichilone N, Imperiale C, Maggi S, et al. Evaluation of health outcomes in elderly patients with asthma and COPD using disease-specific and generic instruments: the Salute Respiratoria nell'Anziano (Sa.R.A.) Study. Chest 2001; 120: 73442.
  • 82
    Beretta L, Santaniello A, Lemos A, Masciocchi M, Scorza R. Validity of the Saint George's Respiratory Questionnaire in the evaluation of the health-related quality of life in patients with interstitial lung disease secondary to systemic sclerosis. Rheumatology (Oxford). 2007; 46: 296301.
  • 83
    Antonioli CM, Bua G, Frige A, Prandini K, Radici S, Scarsi M, et al. An individualized rehabilitation program in patients with systemic sclerosis may improve quality of life and hand mobility. Clin Rheumatol 2009; 28: 15965.
  • 84
    Distler O, Behrens F, Pittrow D, Huscher D, Denton CP, Foeldvari I, et al. Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis. Arthritis Rheum 2008; 59: 86775.
  • 85
    Hatano S, Strasser T. Primary pulmonary hypertension. World Health Organization Geneva: WHO; 1975.
  • 86
    AHA medical/scientific statement. 1994 revisions to classification of functional capacity and objective assessment of patients with diseases of the heart. Circulation 1994; 90: 6445.
  • 87
    Chow S, Pope JE, Mehta S. Lack of correlation of the health assessment questionnaire disability index with lung parameters in systemic sclerosis associated pulmonary arterial hypertension. Clin Exp Rheumatol 2008; 26: 10127.
  • 88
    McKenna SP, Ratcliffe J, Meads DM, Brazier JE. Development and validation of a preference based measure derived from the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for use in cost utility analyses. Health Qual Life Outcomes 2008; 6: 65.
  • 89
    Meads DM, McKenna SP, Doughty N, Das C, Gin-Sing W, Langley J, et al. The responsiveness and validity of the CAMPHOR Utility Index. Eur Respir J 2008; 32: 15139.
  • 90
    Gomberg-Maitland M, Thenappan T, Rizvi K, Chandra S, Meads DM, McKenna SP. United States validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR). J Heart Lung Transplant 2008; 27: 12430.
  • 91
    Coffin D, Duval K, Martel S, Granton J, Lefebvre MC, Meads DM, et al. Adaptation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) into French-Canadian and English-Canadian. Can Respir J 2008; 15: 7783.
  • 92
    Matucci-Cerinic M, Seibold JR. Digital ulcers and outcomes assessment in scleroderma [review]. Rheumatology (Oxford) 2008; 47 Suppl 5: v467.
  • 93
    Toffolo SR, Furtado RN, Klein A, Watanabe S, Andrade LE, Natour J. Measurement of upper limb ulcers in patients with systemic sclerosis: reproducibility and correlation with pain, function, and quality of life. Nurs Res 2008; 57: 8492.
  • 94
    Shenoy PD, Kumar S, Jha LK, Choudhary SK, Singh U, Misra R, Agarwal V. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology (Oxford) 2010; 49: 24208.
  • 95
    Khanna PP, Maranian P, Gregory J, Khanna D. The minimally important difference and patient acceptable symptom state for the Raynaud's condition score in patients with Raynaud's phenomenon in a large randomised controlled clinical trial. Ann Rheum Dis 2010; 69: 58891.
  • 96
    Poole JL. Measures of hand function. Arthritis Care Res (Hoboken) 2011; 63: S18999.
  • 97
    Chung KC, Pillsbury MS, Walters MR, Hayward RA. Reliability and validity testing of the Michigan Hand Outcomes Questionnaire. J Hand Surg Am 1998; 23: 57587.
  • 98
    Mouthon L, Rannou F, Berezne A, Pagnoux C, Arene JP, Fois E, et al. Development and validation of a scale for mouth handicap in systemic sclerosis: the Mouth Handicap in Systemic Sclerosis scale. Ann Rheum Dis 2007; 66: 16515.
  • 99
    Pope JE, Bellamy N. Sample size calculations in scleroderma: a rational approach to choosing outcome measurements in scleroderma trials. Clin Invest Med 1995; 18: 110.